Charles River Laboratories International (CRL) : 14 analysts are covering Charles River Laboratories International (CRL) and their average rating on the stock is 2, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Charles River Laboratories International (CRL) : 9 investment research analysts covering Charles River Laboratories International (CRL) have an average price target of $86.78 for the near short term. The highest target price given by the Brokerage Firm to the stock is $97 and the lowest target is $65 for the short term. Analysts expect the variance to be within $10.01 of the average price.
For the current week, the company shares have a recommendation consensus of Buy.
Charles River Laboratories International (NYSE:CRL): The stock opened at $89.04 on Wednesday but the bulls could not build on the opening and the stock topped out at $89.18 for the day. The stock traded down to $85.76 during the day, due to lack of any buying support eventually closed down at $85.96 with a loss of -1.24% for the day. The stock had closed at $87.04 on the previous day. The total traded volume was 940,074 shares.
Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.